Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Verrica Pharmaceuticals ( (VRCA) ).
On March 31, 2025, Verrica Pharmaceuticals Inc. appointed Dr. Gavin Corcoran as a Class I director, with his term expiring at the 2025 annual meeting of stockholders. Dr. Corcoran, who has extensive experience in the pharmaceutical industry, will receive stock options and an annual retainer as part of his compensation, aligning with the company’s policy for non-employee directors.
More about Verrica Pharmaceuticals
YTD Price Performance: -40.0%
Average Trading Volume: 381,937
Technical Sentiment Signal: Buy
Current Market Cap: $40.59M
For a thorough assessment of VRCA stock, go to TipRanks’ Stock Analysis page.